Alzheimer’s disease (AD), is the most common form of dementia, accounting for between 50-70% of all cases. There is general agreement that current treatments for AD/dementia are inadequate so new treatment strategies are desperately needed. I am addressing these challenges by developing new technologies to generate next generation treatments for AD.
DIREKT: Disarming The Intravascular Innate Immune Response To Improve Modalities For Chronic Kidney Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$362,830.00
Summary
Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.
Restoring Defective Protein Homeostasis In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Frontotemporal dementia (FTD) is associated with pathological accumulation and aggregation of toxic proteins in affected brain regions. This project will employ a novel high throughput drug screening platform technology, FTD patient-derived nerve cells and genetic mouse models to screen drugs to improve clearance of toxic proteins and nerve cell health. This approach should accelerate discovery of agents to potentially treat the underlying cause of FTD in an effort to slow disease progression.
The Missing Link: MGluR5 As A Therapeutic Target For Cognitive Decline In Dementia
Funder
National Health and Medical Research Council
Funding Amount
$563,622.00
Summary
Cognitive decline is a core feature of Alzheimer’s Disease (AD), yet there is no cure or treatment. Recent evidence suggests that a protein called mGluR5 could cause brain cells to lose function, leading to memory loss. This project will investigate whether disrupting mGluR5 function can improve cognition in mice with genetic AD. Memory will be assessed in mice using innovative touchscreen tests that closely mimic the tests used in humans.
OptiMalVax: Optimizing A Deployable High Efficacy Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$494,618.00
Summary
In this proposal, a consortium comprising many of the leading malariologists, vaccine researchers and product developers in Europe, USA, Australia and Africa will collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates against malaria.
Dementia is the third leading cause of death in Australia and the single greatest cause of disability in the elderly. Current therapies for Alzheimer’s disease (AD), the most common form of dementia, are inadequate and fundamentally new treatment approaches are required. The aim of this proposal is to develop novel drug candidates for the treatment and prevention of AD and other neurodegenerative disorders by targeting a class of cell-surface receptors called G protein-coupled receptors (GPCRs).
A Suite Of Engineered Human Pluripotent Stem Cell Lines To Facilitate The Generation Of Hematopoietic Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$881,221.00
Summary
Our goal is to develop tools that address major bottlenecks that have prevented the generation of blood forming stem cells in culture for therapeutic use. We will generate human embryonic stem cell reporter lines that can be used to monitor key milestones in blood stem cell development. These lines will serve as tools to identify growth conditions to improve the differentiation of pluripotent stem cells to functional blood stem cells.
Rolling It Out: Targeted Translation Intervention To Improve Driving Cessation Outcomes For People With Dementia Across Metropolitan And Regional Areas
Funder
National Health and Medical Research Council
Funding Amount
$594,644.00
Summary
This research addresses social, emotional and practical challenges that people with dementia face in dealing with stopping driving. A resource that provides practical and emotional support and education around stopping driving is required in primary care settings to improve quality of life of people with dementia and their carers, and support health professionals who monitor driving issues. This program will translate a research-based resource into GP clinics and community services in Australia.
Choir Participation To Improve Wellbeing And Relationship Quality For Community-dwelling People With Dementia And Their Primary Care-givers
Funder
National Health and Medical Research Council
Funding Amount
$569,698.00
Summary
An estimated 300,000 Australians live with dementia and this figure is projected to triple by 2050. Aligning with government priorities to support primary caregivers to care for loved ones at home, this project investigates the effect of choir participation and familiar music for people with dementia and their caregivers. We expect to find evidence that active music participation enhances wellbeing, quality of life, and relationship quality for people with dementia and their caregivers.
Development And Implementation Of Evidence-based Deprescribing Guidelines To Guide Person-centred Care For People With Dementia
Funder
National Health and Medical Research Council
Funding Amount
$623,363.00
Summary
Optimising medication use in people with dementia will include both initiation of necessary medications and withdrawal of unnecessary and harmful medications. Many guidelines exist to aid doctors when prescribing medication, however, no guidelines currently exist that detail when, or how to withdraw medications. Development and implementation of such guidelines into practice may lead to improved quality of life of people with dementia and their carers.